Quality of reporting in systematic reviews of adverse events: Systematic review

BMJ (Online)

Volumn 348, Issue , 2014, Pages

  Zorzela, Liliane ^a   Golder, Su ^b   Liu, Yali ^c   Pilkington, Karen ^d   Hartling Prof , Lisa ^a   Joffe, Ari ^a   Loke, Yoon ^e   Vohra, Sunita ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF YORK   (United Kingdom)

^c LANZHOU UNIVERSITY   (China)

^d UNIVERSITY OF WESTMINSTER   (United Kingdom)

^e UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE DRUG REACTION; ARTICLE; CLINICAL PRACTICE; COMORBIDITY; DECISION MAKING; DEMOGRAPHY; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; OUTCOME ASSESSMENT; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; RISK FACTOR; SYSTEMATIC REVIEW; VOLUNTARY REPORTING;

CHECKLIST; HUMANS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; REVIEW LITERATURE AS TOPIC;

EID: 84892146092     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f7668     Document Type: Article

References (45)

1. Ioannidis JP. Adverse events in randomized trials: Neglected, restricted, distorted, and silenced. Arch Intern Med 2009;169:1737-9.
2. Sigh S, Loke YK. Drug safety assessment in clinical trials: Methodological challenges and opportunities. Trials 2012;13:138.
3. Papanikolau PN, Ioannidis JP. Availability of large-scale evidence on specific harms from systematic reviews of randomized trials. Am J Med 2004;117:582-9. (Pubitemid 39304209)
4. Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 2009;169:1756-61.
5. Loke YK, Derry S. Reporting of adverse drug reactions in randomized controlled trials - A systematic survey. BMC Clin Pharmacol 2001;1:3.
6. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas. JAMA 2001;285:437-43. (Pubitemid 32097262)
7. Yazici Y. Some concerns about adverse event reporting in randomized clinical trials. Bull NYU Hosp Jt Dis 2008;66:143-5. (Pubitemid 351898382)
8. Ioannidis JP, Evans SJ, Gøtzsche PC, O'Neill RT, Altman DG, Schultz K, et al. Better reporting of harms in randomized clinical trials: An extension of the CONSORT statement. Ann Int Med 2004;141:781-8. (Pubitemid 39524916)
9. McIntosh HM, Woolacott NF, Bagnall AM. Assessing harmful effects in systematic reviews. BMC Med Res Methodol 2004;4:19.
10. Ernst E, Pittler MH. Assessment of therapeutic safety in systematic reviews: literature review. BMJ 2001;323:546. (Pubitemid 32835574)
11. Ernst E, Pittler MH. Systematic reviews neglect safety issues. Arch Intern Med 2001;161:125-6. (Pubitemid 32052156)
12. Aronson JK, Derry S, Loke YK. Adverse drug reactions: keeping up to date. Fundam Clin Pharmacol 2002;16:49-56. (Pubitemid 34298074)
13. Moseley AM, Elkins MR, Herbert RD, Maher CG, Sherrington C. Cochrane reviews used more rigorous methods than non-cochrane reviews: Survey of systematic reviews in physiotherapy. J Clin Epidemiol 2009;62:1021-30.
14. Hopewell S, Wolfenden L, Clarke M. Reporting of adverse events in systematic reviews can be improved: Survey results. J Clin Epidemiol 2007;61:597-602.
15. Moher D, Tetzlaff J, Tricco AC, Sampson M, Altman DG. Epidemiology and reporting characteristics of systematic reviews. PloS Med 2007;4:e78.
16. Golder S, Loke YK, McIntosh HM. Room for improvement? A survey of the methods used in systematic reviews of adverse effects. BMC Med Res Methodol 2006;6:3.
17. Vandermeer B, Bialy L, Johnston B, Hooton N, Hartling L, Klassen TP, et al. Meta-analyses of safety data: A comparison of exact versus asymptotic methods. Stat Methods Med Res 2009;18:421-32.
18. Loke YK, Golder S, Vandenbroucke J. Comprehensive evaluations of the adverse effects of drugs: importance of appropriate study selection and data sources. Ther Adv Drug Saf 2011;2:59-68.
19. Loke YK, Price D, Herxheimer A. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol 2007;7:32.
20. Golder S, Loke YK, McIntosh HM. Poor reporting and inadequate searches were apparent in systematic reviews of adverse effects. J Clin Epidemiol 2008;61:440-8. (Pubitemid 351446183)
21. Golder S, McIntosh HM, Loke YK. Identifying systematic reviews of the adverse effects of health care interventions. BMC Med Res Methodol 2006;6:22.
22. Derry S, Loke YK, Aronson JK. Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med Res Methodol 2001;1:7.
23. Golder S, Loke Y. Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies? Br J Clin Pharmacol 2008;66:767-3.
24. Chou R, Helfand M. Challenges in systematic reviews that assess treatment harms. Ann Intern Med 2005;142:1090-9. (Pubitemid 40847712)
25. Chou R, Aronson N, Atkins D, Ismaila AS, Santaguida P, Smith DH, et al. AHRQ series paper 4: Assessing harms when comparing medical interventions: AHRQ and the effective health care program. J Clin Epi 2010;63:502-12.
26. Cornelius VR, Perrio MJ, Shakir SA, Smith LA. Systematic reviews of adverse effects of drug interventions: A survey of their conduct and reporting quality. Pharmacoepidemiol Drug Saf 2009;18:1223-31.
27. Warren FC, Abrams KR, Golder S, Sutton AJ. Systematic review of methods used in meta-analyses where a primary outcome is an adverse or unintended event. BMC Med Res Methodol 2012;12:64.
28. Golder S, Loke YK, Zorzela L. Some improvements are apparent in identifying adverse effects in systematic reviews from 1994 to 2011. J Clin Epidemiol 2013;66:253-60.
29. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. Cochrane Collaboration, 2011. www.cochranehandbook.org.
30. Moher D, Liberati A, Tetzlaff J, Altman D. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PloS Med 2009;6:e1000097.
31. Moher D, Schulz K, Simera I, Altman D. Guidance for developers of health research reporting guidelines. PloS Med 2010;7:e1000217.
32. Hill AB. The environment and disease: Association or causation? Proc Roy Soc Med 1965;58:295-300.
33. Pilkington K, Boshnakova A. Complementary medicine and safety: A systematic investigation of design and reporting of systematic reviews. Complement Ther Med 2012;20:73-82.
34. Campbell MK, Piaggio G, Elbourne DR, Altman DG. Consort 2010 statement: extension to cluster randomised trials. BMJ 2012;345:e5661.
35. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ. Reporting of non inferiority and equivalence randomized trials: An extension of the CONSORT statement. JAMA 2006;295:1152-60. (Pubitemid 43352345)
36. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG,Tunis S, Haynes B, et al. Improving the reporting of pragmatic trials: An extension of the CONSORT statement. BMJ 2008;337:a2390.
37. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. Reporting randomized, controlled trials of herbal interventions: An elaborated CONSORT statement. Ann Intern Med 2006;144:364-67. (Pubitemid 46768190)
38. Boutron I, Moher D, Altman DG, Schulz K, Ravaud P. Methods and processes of the CONSORT group: example of an extension for trials assessing nonpharmacologic treatments. Ann Intern Med 2008;148:W60-6.
39. MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, et al. STRICTA revision group. Revised standards for reporting interventions in clinical trials of acupuncture (STRICTA): extending the CONSORT statement. PLoS Med 2010;7:e1000261.
40. Newcombe, Robert G. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998;17:857-72.
41. Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 1927;22:209-21.
42. Hammad T, Neyarapally G, Pinheiro S, Iyasu S, Rochester G, Dal Pan G. Reporting of meta-analyses of randomized controlled trials with a focus on drug safety: An empirical assessment. Clin Trials 2013;10:389-97.
43. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007;147:578-81. (Pubitemid 351664507)
44. Hernandez AV, Walker E, Ioannides-Demos LL, Kattan MW. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone. Am Heart J 2008;156:23-30.
45. Shuster JJ, Jones LS, Salmon DA. Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death. Stat Med 2007;26:4375-85. (Pubitemid 47534685)